Compare Stocks

Cellect Biotechnology Ltd. engages in the provision of regenerative medicine. Its activities include development of regenerative medicine through the development of products facilitating immune stem cell selection. The company also develops innovative technology, which allows the default stem cells by dramatically reducing of complications existing in conventional selection methods. The company was founded by Kasbian Nuriel Chirich, Shai Yarkoni, and Nadir Askenasy on August 4, 1986 and is headquartered in Kfar Saba, Israel.

Cytori Therapeutics, Inc. is a late stage cell therapy company, which engages in the development of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. It offers the Cytori Nanomedicine, Cytori Cell Therapy, and other clinical trials. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in San Diego, CA.

Encision Inc., a medical device company, designs, develops, manufactures, and markets patented surgical instruments in the United States. The company provides active electrode monitoring (AEM) surgical instruments and monitors that enhance patient safety and patient outcomes in laparoscopic surgical procedures. Its AEM instruments product line comprises a range of endo-mechanical instruments, including scissors, graspers, and dissectors, as well as fixed-tip electrodes and suction-irrigation electrodes. The company also offers various handles, which are used for advanced laparoscopic procedures that incorporate stiffer shafts and ergonomic features; and AEM EndoShield 2 burn protection systems, as well as markets AEM monitor product line that is used in conjunction with AEM instruments. The company sells its products through a network of direct and independent sales representatives. Encision Inc. was incorporated in 1991 and is based in Boulder, Colorado.

Medite Cancer Diagnostics, Inc. operates as a medical technology company. It develops, manufactures, and markets molecular biomarkers, medical devices, and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions and related diseases. The company offers USE 33, an ultrasonic decalcification instrument that automatically runs the process under controlled temperatures; TPC 15 Duo and Trio, a tissue processing instrument; TES 99 and TES Valida cooling units; and M530, A550, M380 microtomes for tissue sectioning. It also provides M630, a freezing microtome; TST44, a robotic multi-staining system; COT 20, a linear staining system; and RCM 9000, ACS 720, and TWISTER robotic coverslippers. In addition, the company develops SoftKit device for the self-collection of a sample that can be evaluated to provide an assessment of the health of the entire female genital tract. It sells its products through direct sales and distributors in the United States, China, Europe, and North Africa. The company serves histology and cytology laboratories associated with hospitals or research institutions, and independent laboratories. Medite Cancer Diagnostics, Inc. is based in Orlando, Florida.

InVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts. On February 1, 2024, InVivo Therapeutics Holdings Corp. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. It is in joint administration with InVivo Therapeutics Corporation.